Design and baseline characteristics of participants in a phase III randomized trial of celecoxib and selenium for colorectal adenoma prevention

Patricia Thompson, Denise J. Roe, Liane Fales, Julie Buckmeier, Fang Wang, Stanley R. Hamilton, Achyut Bhattacharyya, Sylvan Green, Chiu Hsieh Hsu, H. H. Sherry Chow, Dennis J. Ahnen, C. Richard Boland, Russell I. Heigh, David E. Fay, Maria Elena Martinez, Elizabeth Jacobs, Erin L. Ashbeck, David S. Alberts, Peter Lance

Research output: Contribution to journalArticle

15 Scopus citations

Abstract

COX inhibitors reduce colorectal adenoma recurrence by up to 45% and selenium supplementation may prevent colorectal cancer. Following colonoscopic adenoma resection, 1,600 men and women, ages 40 to 80 years, were randomized to celecoxib (400 mg daily), a selective COX-2 inhibitor, and/or selenium (200 mg daily as selenized yeast), or double placebo. The trial was initiated in November 2001. The primary trial endpoint is adenoma recurrence in each intervention group compared with placebo, as determined by surveillance colonoscopy conducted three to five years after baseline. Randomization was stratified by use of low-dose aspirin (81 mg) and clinic site. Following reports of cardiovascular toxicity associated with COX-2 inhibitors, the celecoxib arm was discontinued in December 2004 when 824 participants had been randomized. Accrual continued with randomization to selenium alone or placebo. Randomization of the originally planned cohort (n = 1,621) was completed in November 2008. A further 200 patients with one or more advanced adenomas (denoting increased risk for colorectal cancer) were accrued to enhance statistical power for determining intervention efficacy in this higher-risk subgroup. Accrual of the total cohort (n = 1,824) was completed in January 2011. Baseline cohort characteristics include: mean age 62.9 years; 65% male; body mass index (BMI) 29.1 ± 5.1; 47% taking low-dose aspirin while on trial; 20% with three or more adenomas; and 38% with advanced adenomas. Intervention effects on adenoma recurrence will be determined, and their modification by genetic background and baseline selenium level. The effect of selenium supplementation on risk for type II diabetes will also be reported.

Original languageEnglish (US)
Pages (from-to)1381-1393
Number of pages13
JournalCancer Prevention Research
Volume5
Issue number12
DOIs
StatePublished - Dec 2012

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Design and baseline characteristics of participants in a phase III randomized trial of celecoxib and selenium for colorectal adenoma prevention'. Together they form a unique fingerprint.

  • Cite this

    Thompson, P., Roe, D. J., Fales, L., Buckmeier, J., Wang, F., Hamilton, S. R., Bhattacharyya, A., Green, S., Hsu, C. H., Sherry Chow, H. H., Ahnen, D. J., Boland, C. R., Heigh, R. I., Fay, D. E., Martinez, M. E., Jacobs, E., Ashbeck, E. L., Alberts, D. S., & Lance, P. (2012). Design and baseline characteristics of participants in a phase III randomized trial of celecoxib and selenium for colorectal adenoma prevention. Cancer Prevention Research, 5(12), 1381-1393. https://doi.org/10.1158/1940-6207.CAPR-12-0204